The 483

Tag

Phase 3

25 stories

Deals

Lilly Paid $3.2B for Kelonia's 100% CAR-T Response

Lilly Paid $3.2B for Kelonia's 100% CAR-T Response
FDA

FDA Cleared Lilly Foundayo in $9.3B Obesity Race

FDA Cleared Lilly Foundayo in $9.3B Obesity Race
FDA

Paid $270M for BMN 401, BioMarin Misses Phase 3

Paid $270M for BMN 401, BioMarin Misses Phase 3
FDA

Celcuity Beats Piqray in Phase 3, Shares Jump 15%

Celcuity Beats Piqray in Phase 3, Shares Jump 15%
FDA

Roche Fenebrutinib Clears Phase 3, Carries 8-to-1 Death Gap

Roche Fenebrutinib Clears Phase 3, Carries 8-to-1 Death Gap
FDA

Trump Backs FDA Push to Fast-Track Psychedelic Treatments

Trump Backs FDA Push to Fast-Track Psychedelic Treatments
FDA

RevMed Doubles Phase 3 Survival With Pan-RAS Drug at AACR25

RevMed Doubles Phase 3 Survival With Pan-RAS Drug at AACR25
FDA

Merck Hits 55% NSCLC ORR With MK-2010, Won't Commit to Phase 3

Merck Hits 55% NSCLC ORR With MK-2010, Won't Commit to Phase 3
Deals

Raised $625M at $16 a Share, Kailera Tops Moderna's 2018 IPO Record

Raised $625M at $16 a Share, Kailera Tops Moderna's 2018 IPO Record
Deals

Revolution Doubles Offering to $2B at $142 After Daraxonrasib Phase 3 Win

Revolution Doubles Offering to $2B at $142 After Daraxonrasib Phase 3 Win
FDA

Doubles PDAC Survival: Revolution Jumps 40% on Daraxonrasib Phase 3 Data

Doubles PDAC Survival: Revolution Jumps 40% on Daraxonrasib Phase 3 Data
FDA

FDA Cleared Filspari for FSGS Despite Phase 3 Fail, Opening $2B Market

FDA Cleared Filspari for FSGS Despite Phase 3 Fail, Opening $2B Market
FDA

IDEAYA Files FDA: Darovasertib Doubles PFS to 6.9 Months

IDEAYA Files FDA: Darovasertib Doubles PFS to 6.9 Months
FDA

Beats Venetoclax: Lilly's Jaypirca Posts 4th Phase 3 Win in CLL

Beats Venetoclax: Lilly's Jaypirca Posts 4th Phase 3 Win in CLL
FDA

Revolution Medicines' Daraxonrasib Succeeds in Phase 3 Registrational Trial

Revolution Medicines' Daraxonrasib Succeeds in Phase 3 Registrational Trial
FDA

Cleared Phase 3: Daraxonrasib Hits 13.2-Month OS in Pancreatic Cancer

Cleared Phase 3: Daraxonrasib Hits 13.2-Month OS in Pancreatic Cancer
Deals

Regeneron Paid $40M to Enter Radiopharma; Telix Scores Up to $4.3B

Regeneron Paid $40M to Enter Radiopharma; Telix Scores Up to $4.3B
FDA

GSK Races mo-rez Into 5 Phase 3 Trials After 62% Ovarian ORR

GSK Races mo-rez Into 5 Phase 3 Trials After 62% Ovarian ORR
FDA

FDA Cleared Foundayo; Lilly Pre-Stocked $1.5B Before Approval

FDA Cleared Foundayo; Lilly Pre-Stocked $1.5B Before Approval
FDA

Bets Five Phase 3 Studies on Hansoh ADC: GSK Targets Gynecological Cancers

Bets Five Phase 3 Studies on Hansoh ADC: GSK Targets Gynecological Cancers
Deals

Gilead Spends $14.77B on Three Deals, Then Hits Pause

Gilead Spends $14.77B on Three Deals, Then Hits Pause
FDA

Lilly Foundayo Clears FDA; Novo's Oral Holds 5-Point Lead

Lilly Foundayo Clears FDA; Novo's Oral Holds 5-Point Lead
FDA

Amgen's Tepezza Just Got Injectable Data. So Did Viridian.

Amgen's Tepezza Just Got Injectable Data. So Did Viridian.
FDA

Lunsekimig Fails Eczema Phase 2, Leaving Dupixent Without a Successor

Lunsekimig Fails Eczema Phase 2, Leaving Dupixent Without a Successor
FDA

Lipocine's PPD Drug Fails Phase 3, Stock Craters 77%

Lipocine's PPD Drug Fails Phase 3, Stock Craters 77%